Life-threatening adverse event after amphotericin B lipid complex treatment in a patient treated previously with amphotericin B deoxycholate.
Garnacho-Montero
J
J
Intensive Care Unit, Hospital Universitario Virgen Del Rocio, Seville, Spain.
Ortiz-Leyba
C
C
García Garmendia
J L
JL
Jiménez Jiménez
F
F
D000666:Amphotericin B / Q000009:adverse effects* / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002177:Candidiasis / Q000150:complications* / Q000188:drug therapy; D003840:Deoxycholic Acid / Q000627:therapeutic use*; D004338:Drug Combinations; D006801:Humans; D008297:Male; D008875:Middle Aged; D010713:Phosphatidylcholines / Q000009:adverse effects* / Q000627:therapeutic use; D010715:Phosphatidylglycerols / Q000009:adverse effects* / Q000627:therapeutic use; D012120:Respiration Disorders / Q000139:chemically induced*
D000935:Antifungal Agents; D004338:Drug Combinations; D010713:Phosphatidylcholines; D010715:Phosphatidylglycerols; C068538:liposomal amphotericin B; D003840:Deoxycholic Acid; D000666:Amphotericin B; C059765:amphotericin B, deoxycholate drug combination